Dr David Boettiger

Senior Research Fellow

Qualifications:

PhD, UNSW Sydney, 2016; MSc Epidemiology, Utrecht University, 2011; MSc Pharmacy, Newcastle University, 2005; BSc Biomedical Science, Newcastle University, 2003.

Location:

Newcastle

Biography:

Dr Boettiger uses his detailed knowledge of epidemiology, biostatistics, and health economics to analyse large trials and cohorts, and build quantitative models that address key infectious disease concerns. His research is cited in international guidelines on the use of antiretroviral therapy and has significantly enhanced the lives of people living with HIV. Dr Boettiger's expertise in HIV and viral hepatitis has led to collaborations with the World Health Organization, World Bank, US Centers for Disease Control and Prevention, and US National Institutes for Health. He serves on the board of the Australian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) international committee and as an editorial board member for JAIDS and Health Policy and Planning - both leading journals for research in resource-limited areas. He also holds an academic appointment at the Kirby Institute, UNSW Sydney and academic affiliations with the University of California San Francisco (USA) and Chulalongkorn University (Thailand). 

Dr David Boettiger
Email
Research Themes
  1. BOETTIGER DC, Nguyen VK, Durier N, Bui HV, Heng Sim BL, Azwa I, Law M, Ruxrungtham K. Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database. Journal of Acquired Immune Deficiency Syndrome (2014) 68(2):186-95 (DOI: 10.1097/QAI.0000000000000411)
  2. BOETTIGER DC, Kerr S, Ditangco R, Merati TP, Thanh Pham TT, Chaiwarith R, Kiertiburanakul S, Li CKP, Kumarasamy N, Vonthanak S, Lee C, Kinh NV, Pujari S, Wong WW, Kamarulzaman A, Zhang F, Yunihastuti E, Choi JY, Oka S, Ng OT, Kantipong P, Mustafa M, Ratanasuwan W, Sohn A, Law M. Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. Plos One (2014) 9(9):e106525 (DOI: 10.1371/journal.pone.0106525)
  3. Kiertiburanakul S, BOETTIGER DC, Lee MP, Omar SF, Tanuma J, Ng OT, Durier N, Phanuphak P, Ditangco R, Chaiwarith R, Kantipong P, Lee CK, Mustafa M, Saphonn V, Ratanasuwan W, Merati TP, Kumarasamy N, Wong WW, Zhang F, Pham TT, Pujari S, Choi JY, Yunihastuti E, Sungkanuparph S. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. Journal of the International AIDS Society (2014) 17:18804 (DOI: 10.7448/IAS.17.1.18804)
  4. BOETTIGER DC, Muktiarti D, Kurniati N, Truong KH, Saghayam S, Ly PS, Hansudewechakul R, Van Nguyen L, Do VC, Sudjaritruk T, Lumbiganon P, Chokephaibulkit K, Bunupuradah T, Nik Yusoff NK, Wati DK, Mohd Razali KA, Fong MS, Nallusamy RA, Sohn AH, Kariminia A. Early Height and Weight Changes in Children Using Cotrimoxazole Prophylaxis with Antiretroviral Therapy. Clinical Infectious Diseases (2016) 63(9):1236-1244 (DOI: 10.1093/cid/ciw514)
  5. BOETTIGER DC, Sudjaritruk T, Nallusamy R, Lumbiganon P, Rungmaitree S, Hansudewechakul R, Kumarasamy N, Bunupuradah T, Saphonn V, Truong KH, Yusoff NK, Do VC, Nguyen LV, Razali KA, Fong SM, Kurniati N, Kariminia A. Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naive Adolescents in Asia. Journal of Adolescent Health (2016) 58(4):451-459 (DOI: 10.1016/j.jadohealth.2015.11.006)
  6. BOETTIGER DC, Sabin CA, Grulich A, Ryom L, Bonnet F, Reiss P, d'arminio Monforte A, Kirk O, Phillips A, Bower M, Fätkenheuer G, Lundgren JD, Law M. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS (2016) 30(10):1629-1637 (DOI: 10.1097/QAD.0000000000001053)
  7. BOETTIGER DC, Salazar-Vizcaya L (my postdoc and co-first author), Dore GJ, Gray RT, Law MG, Callander D, Lea T, Rauch A, Matthews GV. Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus-positive Gay and Bisexual Men? Clinical Infectious Diseases (2019) 70(1):106-113 (DOI: 10.1093/cid/ciz164)
  8. BOETTIGER DC, Newall AT, Chattranukulchai P, Chaiwarith R, Khusuwan S, Avihingsanon A, Phillips A, Bendavid E, Law MG, Kahn JG, Ross J, Bautista-Arredondo S, Kiertiburanakul S. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. Journal of the International AIDS Society (2020) 23 Suppl 1:e25494 (DOI: 10.1002/jia2.25494)
  9. Han WM, Kerr SJ, Avihingsanon A, BOETTIGER DC. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV. Journal of Antimicrobial Chemotherapy (2022) 77(12):3242-3247 (DOI: 10.1093/jac/dkac306)
  10. Cheng Q, Poynten IM, Jin F, Grulich A, Ong JJ, Hillman RJ, Hruby G, Howard K, Newall A, BOETTIGER DC. Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV. Lancet Regional Health Western Pacific (2023) Online 100676 (DOI: 10.1016/j.lanwpc.2022.100676)